Form 4: MoonLake Immunotherapeutics Chief Scientific Officer Reports Share Transactions

Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, reports the exchange of MoonLake AG shares for Class A ordinary shares and the cancellation of Class C ordinary shares.

Summary

• Kristian Reich, the Chief Scientific Officer of MoonLake Immunotherapeutics, has reported a transaction involving the exchange of 3,328 common shares of MoonLake AG for 111,949 Class A ordinary shares of MoonLake Immunotherapeutics on January 20, 2025.
• Simultaneously, 111,949 Class C ordinary shares of MoonLake Immunotherapeutics were automatically cancelled as part of this exchange.
• Reich also directly owns 153,930 Class A ordinary shares and indirectly owns 2,925,573 Class A ordinary shares through JeruCON Beratungsgesellschaft mbH.
• The common shares of MoonLake AG can be exchanged for Class A ordinary shares at a rate of 1 to 33.638698, with corresponding Class C shares being cancelled upon exchange.
• 10,000 of Reich's MoonLake AG shares are subject to a reverse vesting schedule, with full vesting expected by January 18, 2026, and accelerated vesting upon a change of control of MoonLake AG.
• Unvested shares can be repurchased by MoonLake AG at a nominal value of CHF 0.10 per share under certain termination conditions.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of insider transactions and does not indicate any positive or negative sentiment.

Risks

• The reverse vesting condition on 10,000 MoonLake AG shares could be impacted by termination of employment or a change of control of MoonLake AG.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders reporting changes in their beneficial ownership of company stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States, ensuring transparency of insider transactions.
• The share exchange and vesting conditions are not unusual for executive compensation packages in the biotech industry.
• Similar filings can be seen from executives at companies such as Regeneron, Amgen, and Gilead, which also have complex share structures and vesting schedules.

Stakeholder Impact

• The share transactions reported in this document may be of interest to shareholders as they provide insight into the ownership structure and insider activity of the company.

Key Dates

Keywords

MoonLake Immunotherapeutics, share transaction, Class A ordinary shares, Class C ordinary shares, MoonLake AG, Kristian Reich, beneficial ownership, reverse vesting